Corvus Pharmaceuticals (CRVS) Competitors $4.13 -0.04 (-0.96%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$4.14 +0.01 (+0.27%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, DYN, SANA, and RCUSShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), Dyne Therapeutics (DYN), Sana Biotechnology (SANA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Sana Biotechnology Arcus Biosciences Cidara Therapeutics (NASDAQ:CDTX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Do insiders and institutionals hold more shares of CDTX or CRVS? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by company insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer CDTX or CRVS? Cidara Therapeutics currently has a consensus price target of $57.29, suggesting a potential downside of 7.20%. Corvus Pharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 263.20%. Given Corvus Pharmaceuticals' higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CDTX or CRVS more profitable? Corvus Pharmaceuticals' return on equity of -24.04% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -73.04% -54.28% Corvus Pharmaceuticals N/A -24.04%-13.90% Which has more risk and volatility, CDTX or CRVS? Cidara Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Does the media refer more to CDTX or CRVS? In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Cidara Therapeutics. MarketBeat recorded 4 mentions for Corvus Pharmaceuticals and 3 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 0.86 beat Corvus Pharmaceuticals' score of 0.20 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, CDTX or CRVS? Corvus Pharmaceuticals has lower revenue, but higher earnings than Cidara Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.27M979.90-$169.83M-$29.47-2.09Corvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.21 SummaryCorvus Pharmaceuticals beats Cidara Therapeutics on 8 of the 15 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$284.27M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-4.2117.9729.8525.14Price / SalesN/A262.52422.3397.16Price / CashN/A41.8335.9458.58Price / Book8.107.238.125.59Net Income-$62.29M-$54.43M$3.26B$265.48M7 Day Performance0.73%0.22%0.68%1.22%1 Month Performance4.29%5.59%2.46%0.39%1 Year Performance15.04%9.98%27.99%23.47% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.5845 of 5 stars$4.13-1.0%$15.00+263.2%+25.5%$284.27MN/A-4.2130News CoverageEarnings ReportCDTXCidara Therapeutics3.3764 of 5 stars$62.68+1.3%$57.29-8.6%+456.1%$1.25B$1.27M-2.1390Earnings ReportCVACCureVac4.466 of 5 stars$5.42-0.7%$6.83+26.1%+64.5%$1.22B$579.18M5.89880News CoverageUpcoming EarningsAUPHAurinia Pharmaceuticals2.1471 of 5 stars$8.89-0.4%$11.50+29.4%+114.8%$1.21B$235.13M31.75300Insider TradePRAXPraxis Precision Medicines1.6617 of 5 stars$55.65-6.0%$94.11+69.1%-9.1%$1.21B$8.55M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.0912 of 5 stars$28.92-0.9%$24.40-15.6%+60.8%$1.18B$1.02B37.081,940Positive NewsSRPTSarepta Therapeutics4.6213 of 5 stars$13.86+16.2%$51.42+271.0%-87.2%$1.17B$1.90B-5.151,372Trending NewsEarnings ReportAnalyst ForecastGap UpDYNDyne Therapeutics3.3786 of 5 stars$9.31-6.4%$40.63+336.4%-73.5%$1.13BN/A-2.59100Upcoming EarningsAnalyst ForecastSANASana Biotechnology3.2996 of 5 stars$4.88-1.4%$9.17+87.8%-37.1%$1.12BN/A-5.55380News CoverageUpcoming EarningsGap DownRCUSArcus Biosciences2.1011 of 5 stars$9.85-3.7%$21.29+116.1%-33.4%$1.08B$258M-2.35500Earnings ReportAnalyst ForecastGap Up Related Companies and Tools Related Companies Cidara Therapeutics Alternatives CureVac Alternatives Aurinia Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Sarepta Therapeutics Alternatives Dyne Therapeutics Alternatives Sana Biotechnology Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
